Clinical Trial Update: A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination of vemurafenib, cytarabine, and 2-chlorodeoxyadenosine in children with Langerhans Cell Histiocytosis harboring BRAF V600…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Langerhans Cell Histiocytosis

Drugs mentioned

• 2-chlorodeoxyadenosine (2-chlorodeoxyadenosine)
• CYTARABINE (CYTARABINE)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Conditions: Langerhans Cell Histiocytosis | Phase 2 | Status: UNKNOWN